Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

NCT04533321 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT04533321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04533321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2020
Completion date
September 30, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma